Lactic acid bacteria isolated from mother's milk with probiotic activity and inhibitory activity against body weight augmentation

Abstract

The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.

What is claimed is: 
     
       1. A Lactobacillus gasseri BNR17 strain of a biologically pure culture deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 
     
     
       2. The Lactobacillus gasseri BNR17 strain according to  claim 1 , wherein the strain contains 16S rRNA sequence represented by SEQ ID NO: 1. 
     
     
       3. A composition containing an effective dose of the Lactobacillus gasseri BNR17 of  claim 1 . 
     
     
       4. The composition according to  claim 3 , wherein the composition is selected from the group consisting of food, food additive, animal feed and animal feed additive. 
     
     
       5. The composition according to  claim 4 , wherein the animal feed additive contains at least one selected from the group consisting of other non-pathogenic microorganisms, enzymes and a mixture thereof. 
     
     
       6. A pharmaceutical composition comprising an effective dose of the Lactobacillus gasseri BNR17 of  claim 1 . 
     
     
       7. A culture solution of the Lactobacillus gasseri BNR17 of  claim 1 . 
     
     
       8. A method for inhibiting weight gain comprising administering to a subject an effective dose of the Lactobacillus gasseri BNR17 of  claim 1 . 
     
     
       9. A composition comprising Lactobacillus gasseri BNR17 strain in an enteric coating, wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP. 
     
     
       10. The composition of claim 9, which further comprises (a) one or more selected from the group consisting of acacia gum, calcium phosphate, alginate, tragacanth gum, calcium silicate, silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil, and (b) one or more selected from the group consisting of a lactose, dextrose, sucrose, sorbitol, mannitol, starch, gelatin, and water. 
     
     
       11. The composition of claim 9, which is in a form of capsule or tablet. 
     
     
       12. The composition of claim 9, which further comprises one or more additional probiotic microorganism selected from the group consisting of Saccharomyces cerevisiae, Bacillus coagulans, Bacillus licheniformis, Bacillus subtilis, Bifidobacterium bifidum, Bifidobacterium infantis, Bifidobacterium longum, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus alimentarius, Lactobacillus casei, Lactobacillus curvatus, Lactobacillus delbruckii, Lactobacillus johnsonii, Lactobacillus farciminus, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus reuteri, Lactobacillus sakei, Lactococcus lactis and Pediococcus acidilactici. 
     
     
       13. A dry powder comprising live Lactobacillus gasseri cells and a protectant, wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, and wherein the protectant comprises powdered skim milk, whey, and/or sucrose. 
     
     
       14. A method of producing a product, comprising mixing a dry powder of claim 13 with at least one substance selected from the group a diluent, a high-fiber additive, an encapsulant, a lipid, an enzyme and a non-pathogenic microorganism,
 wherein the live Lactobacillus gasseri cells are of the Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP; and   wherein the protectant comprises powdered skim milk, whey, and/or sucrose.   
     
     
       15. A culture comprising a culture medium and Lactobacillus gasseri BNR17, wherein the culture is obtained by culturing the Lactobacillus gasseri BNR17 in a culture medium suitable for Lactobacillus gasseri BNR17;
 wherein the L. gasseri BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP;   wherein the culture comprises an extracellular polysaccharide produced by the Lactobacillus gasseri BNR17; and   wherein the culturing is carried out for 12-36 hours.   
     
     
       16. The culture of claim 15, wherein the culture medium is an MRS medium supplemented with 2% glucose. 
     
     
       17. A method for inhibiting growth of a pathogenic bacterium in intestine of a subject in need thereof comprising administering Lactobacillus gasseri BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, to the subject, wherein the pathogenic bacterium is selected from the group consisting of E. coli, B. cereus, L. monocytogenes, P. mirabilis, S. aureus, and S. typhimurium.